Episode
Three BLAs, Three Journeys, with Irving Ford, Megan Callan, and Jake Treese
- Podcast
- Let's Talk Quality
- Published
- May 7, 2026
- Duration seconds
- 2094
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/let-s-talk-quality-6567110/episodes/three-blas-three-journeys-with-irving-ford-megan-callan-and-jake-treese/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/let-s-talk-quality-6567110/three-blas-three-journeys-with-irving-ford-megan-callan-and-jake-treese.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Three BLAs. Three companies. One industry-defining challenge. Jake Trees, Irving Ford, and Megan Callan on What It Really Takes to Cross the Commercial Line in Cell and Gene Therapy In this special compiled episode of Let's Talk Quality, Hemish Ilangaratne brings together three quality leaders who have each led their organisation through one of the most demanding transitions in the industry: from clinical development to commercial manufacturing for a cell or gene therapy product. Jake Trees spent five years at Bristol Myers Squibb leading the quality function through the approval and launch of Abecma and Breyanzi, two of the first commercially approved CAR T cell therapies in the world. Irving Ford was the first quality hire at the Celgene cell therapy facility in New Jersey, built the QC organisation from nothing, and has since led quality through four BLA approvals across multiple cell therapy companies, most recently at Adaptimmune for the approval of Aucatzyl. Megan Callan is VP of Quality at Abeona Therapeutics, where she guided the quality team through the FDA approval of Zevaskyn, the first ever approved topical gene therapy for a rare genetic skin disorder. These are three distinct products, three distinct companies, and three distinct leadership journeys. But across all three conversations, the same themes surface: what it takes to build a quality team from scratch, how to shift the mindset of a clinical organisation towards commercial standards, and what the moment of approval actually feels like after years of sustained effort. In this episode, you will hear the following: Jake Trees on the setbacks on the road to BLA approval, including a refusal to file, cell growth failures during scale-up, and leading through a pandemic while hosting three health authori…